Sana Biotechnology (NASDAQ:SANA) Trading Up 9.7% – What’s Next?

Sana Biotechnology, Inc. (NASDAQ:SANA) was up 9.7% on Tuesday . The company traded as high as $2.79 and last traded at $2.77. Approximately 1,703,763 shares changed hands during mid-day trading, a decline of 42% from the average daily volume of 2,954,771 shares. The stock had previously closed at $2.52.

Analyst Ratings Changes

Several equities analysts have recently issued reports on the company. TD Cowen raised Sana Biotechnology from a “hold” rating to a “buy” rating in a report on Wednesday, January 8th. HC Wainwright upped their price objective on Sana Biotechnology from $8.00 to $11.00 and gave the company a “buy” rating in a research note on Wednesday, January 8th. One analyst has rated the stock with a hold rating and four have given a buy rating to the company’s stock. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus price target of $14.00.

Sana Biotechnology Stock Performance

The company has a market cap of $613.99 million, a PE ratio of -1.96 and a beta of 1.63. The company’s 50 day moving average price is $2.93 and its 200-day moving average price is $3.34.

Insider Buying and Selling at Sana Biotechnology

In related news, insider Fmr Llc sold 290,912 shares of the business’s stock in a transaction dated Wednesday, January 8th. The stock was sold at an average price of $6.49, for a total value of $1,888,018.88. Following the sale, the insider now directly owns 4,541,511 shares in the company, valued at approximately $29,474,406.39. The trade was a 6.02 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. 31.10% of the stock is owned by corporate insiders.

Institutional Trading of Sana Biotechnology

Several hedge funds and other institutional investors have recently modified their holdings of the business. FMR LLC grew its stake in Sana Biotechnology by 16.3% in the 3rd quarter. FMR LLC now owns 31,609,175 shares of the company’s stock valued at $131,494,000 after buying an additional 4,438,949 shares in the last quarter. State Street Corp boosted its holdings in shares of Sana Biotechnology by 4.2% in the third quarter. State Street Corp now owns 6,627,320 shares of the company’s stock worth $27,570,000 after acquiring an additional 269,274 shares during the period. Geode Capital Management LLC boosted its holdings in shares of Sana Biotechnology by 0.8% in the fourth quarter. Geode Capital Management LLC now owns 3,193,081 shares of the company’s stock worth $5,206,000 after acquiring an additional 26,601 shares during the period. Price T Rowe Associates Inc. MD grew its position in shares of Sana Biotechnology by 7.6% in the fourth quarter. Price T Rowe Associates Inc. MD now owns 3,108,617 shares of the company’s stock valued at $5,068,000 after purchasing an additional 219,498 shares in the last quarter. Finally, Integral Health Asset Management LLC raised its stake in shares of Sana Biotechnology by 11.1% during the 4th quarter. Integral Health Asset Management LLC now owns 2,000,000 shares of the company’s stock valued at $3,260,000 after purchasing an additional 200,000 shares during the period. Institutional investors own 88.23% of the company’s stock.

About Sana Biotechnology

Sana Biotechnology, Inc, a biotechnology company, focuses on utilizing engineered cells as medicines. It develops ex vivo and in vivo cell engineering platforms for various therapeutic areas with unmet treatment needs, including oncology, diabetes, central nervous system disorders, B-cell-mediated autoimmune, and others.